LabGenius

LabGenius is a startup based in the United Kingdom. Its most recent tracked round is Series B. Brouky records 3 investors associated with the company.

LabGenius is a biopharmaceutical company that utilizes machine learning, synthetic biology, and robotics to accelerate the discovery of next-generation therapeutic antibodies. Their platform, EVA™, enables the rapid identification of high-performing antibodies with non-intuitive designs through an iterative process called active learning.